Guardant Health (NASDAQ:GH) Director Musa Tariq Sells 116 Shares of Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the business’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $101.46, for a total value of $11,769.36. Following the sale, the director owned 7,993 shares in the company, valued at approximately $810,969.78. The trade was a 1.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Musa Tariq also recently made the following trade(s):

• On Wednesday, November 19th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $96.25, for a total value of $11,165.00.
• On Friday, October 17th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $66.95, for a total transaction of $7,766.20.

Guardant Health Stock Up 0.7%

Shares of GH stock opened at $97.80 on Friday. The stock has a market cap of $12.33 billion, a price-to-earnings ratio of -30.46 and a beta of 1.58. The firm’s 50 day moving average price is $91.51 and its two-hundred day moving average price is $67.00. Guardant Health, Inc. has a fifty-two week low of $29.91 and a fifty-two week high of $112.43.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. Guardant Health’s quarterly revenue was up 38.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.88) earnings per share. On average, equities analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GH. Evercore ISI increased their price objective on Guardant Health from $68.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Wells Fargo & Company increased their price target on shares of Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday. Wolfe Research upgraded shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price objective on the stock in a research note on Thursday, September 25th. William Blair reissued an “outperform” rating on shares of Guardant Health in a research report on Thursday, September 25th. Finally, Mizuho raised their price objective on Guardant Health from $100.00 to $120.00 and gave the company an “outperform” rating in a research note on Wednesday. Twenty-three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.52.

Institutional Trading of Guardant Health

Hedge funds have recently bought and sold shares of the stock. Cetera Investment Advisers acquired a new position in Guardant Health during the first quarter valued at approximately $211,000. PNC Financial Services Group Inc. boosted its stake in shares of Guardant Health by 25.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company’s stock valued at $112,000 after purchasing an additional 537 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Guardant Health during the 1st quarter valued at $3,151,000. HighTower Advisors LLC grew its stake in shares of Guardant Health by 0.9% in the first quarter. HighTower Advisors LLC now owns 51,107 shares of the company’s stock worth $2,177,000 after purchasing an additional 469 shares during the last quarter. Finally, American Century Companies Inc. grew its position in shares of Guardant Health by 0.3% in the 1st quarter. American Century Companies Inc. now owns 104,206 shares of the company’s stock valued at $4,439,000 after buying an additional 282 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.